(2HQ.DE) Fundamental Analysis & Valuation

FRA:2HQ • US88688T1007

Current stock price

0.679 EUR
-0.04 (-5.19%)
Last:

This 2HQ.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. 2HQ.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 2HQ has reported negative net income.
  • In the past year 2HQ has reported a negative cash flow from operations.
  • 2HQ had negative earnings in each of the past 5 years.
  • 2HQ had negative operating cash flow in 4 of the past 5 years.
2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCF2HQ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500M -1B -1.5B -2B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -103.13%, 2HQ is doing worse than 87.27% of the companies in the same industry.
  • 2HQ has a Return On Equity of -139.41%. This is amonst the worse of the industry: 2HQ underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -103.13%
ROE -139.41%
ROIC N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
2HQ.DE Yearly ROA, ROE, ROIC2HQ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

  • 2HQ has a Gross Margin of 28.69%. This is in the lower half of the industry: 2HQ underperforms 76.36% of its industry peers.
  • In the last couple of years the Gross Margin of 2HQ has grown nicely.
  • 2HQ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2HQ.DE Yearly Profit, Operating, Gross Margins2HQ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. 2HQ.DE Health Analysis

2.1 Basic Checks

  • 2HQ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 2HQ has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for 2HQ has been increased compared to 5 years ago.
  • The debt/assets ratio for 2HQ is higher compared to a year ago.
2HQ.DE Yearly Shares Outstanding2HQ.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
2HQ.DE Yearly Total Debt VS Total Assets2HQ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • 2HQ has an Altman-Z score of -2.63. This is a bad value and indicates that 2HQ is not financially healthy and even has some risk of bankruptcy.
  • 2HQ's Altman-Z score of -2.63 is on the low side compared to the rest of the industry. 2HQ is outperformed by 80.00% of its industry peers.
  • A Debt/Equity ratio of 0.18 indicates that 2HQ is not too dependend on debt financing.
  • 2HQ has a Debt to Equity ratio of 0.18. This is in the better half of the industry: 2HQ outperforms 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -2.63
ROIC/WACCN/A
WACC5.65%
2HQ.DE Yearly LT Debt VS Equity VS FCF2HQ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • 2HQ has a Current Ratio of 2.62. This indicates that 2HQ is financially healthy and has no problem in meeting its short term obligations.
  • 2HQ has a better Current ratio (2.62) than 85.45% of its industry peers.
  • 2HQ has a Quick Ratio of 1.56. This is a normal value and indicates that 2HQ is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of 2HQ (1.56) is better than 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.56
2HQ.DE Yearly Current Assets VS Current Liabilites2HQ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 2HQ.DE Growth Analysis

3.1 Past

  • The earnings per share for 2HQ have decreased strongly by -6498.00% in the last year.
  • Looking at the last year, 2HQ shows a small growth in Revenue. The Revenue has grown by 2.31% in the last year.
  • Measured over the past years, 2HQ shows a very strong growth in Revenue. The Revenue has been growing by 37.52% on average per year.
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.94% on average over the next years. This is quite good.
  • Based on estimates for the next years, 2HQ will show a small growth in Revenue. The Revenue will grow by 4.31% on average per year.
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
2HQ.DE Yearly Revenue VS Estimates2HQ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
2HQ.DE Yearly EPS VS Estimates2HQ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

1

4. 2HQ.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 2HQ. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2HQ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2HQ.DE Price Earnings VS Forward Price Earnings2HQ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 2HQ is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.73
2HQ.DE Per share data2HQ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • 2HQ's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.34%
EPS Next 3Y25.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 2HQ.DE Dividend Analysis

5.1 Amount

  • No dividends for 2HQ!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

2HQ.DE Fundamentals: All Metrics, Ratios and Statistics

FRA:2HQ (12/1/2025, 7:00:00 PM)

0.679

-0.04 (-5.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-09
Earnings (Next)01-08
Inst Owners10.33%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap78.76M
Revenue(TTM)830.77M
Net Income(TTM)-2.15B
Analysts71.25
Price Target14.74 (2070.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2631.48%
Min EPS beat(2)-5362.97%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-1385.84%
Min EPS beat(4)-5362.97%
Max EPS beat(4)100%
EPS beat(8)2
Avg EPS beat(8)-708.23%
EPS beat(12)2
Avg EPS beat(12)-746.7%
EPS beat(16)4
Avg EPS beat(16)-606.4%
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.23%
Max Revenue beat(2)0.41%
Revenue beat(4)1
Avg Revenue beat(4)-6.19%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)0.41%
Revenue beat(8)1
Avg Revenue beat(8)-5.71%
Revenue beat(12)2
Avg Revenue beat(12)-3.59%
Revenue beat(16)2
Avg Revenue beat(16)-3.93%
PT rev (1m)786.17%
PT rev (3m)1526.36%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-788.89%
EPS NY rev (1m)-19.05%
EPS NY rev (3m)54.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.12
EV/EBITDA 2.73
EPS(TTM)-11.25
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS6.11
BVpS11.32
TBVpS5.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -103.13%
ROE -139.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.69%
FCFM N/A
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA 6.5
Cap/Depr 30.45%
Cap/Sales 4.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.56
Altman-Z -2.63
F-Score3
WACC5.65%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
EBIT growth 1Y28.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.61%
EBIT Next 3Y29.12%
EBIT Next 5Y17.36%
FCF growth 1Y-688.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.17%
OCF growth 3YN/A
OCF growth 5YN/A

/ 2HQ.DE Fundamental Analysis FAQ

What is the fundamental rating for 2HQ stock?

ChartMill assigns a fundamental rating of 2 / 10 to 2HQ.DE.


What is the valuation status for 2HQ stock?

ChartMill assigns a valuation rating of 1 / 10 to (2HQ.DE). This can be considered as Overvalued.


What is the profitability of 2HQ stock?

(2HQ.DE) has a profitability rating of 1 / 10.


What is the financial health of (2HQ.DE) stock?

The financial health rating of (2HQ.DE) is 3 / 10.


Can you provide the expected EPS growth for 2HQ stock?

The Earnings per Share (EPS) of (2HQ.DE) is expected to grow by 99.61% in the next year.